Acute myeloblastic leukaemia--a model for assessing value for money for new treatment programmes.

Lobo, P J; Powles, R L; Hanrahan, A; Reynold, D K

Lobo, P J; Powles, R L; Hanrahan, A; Reynold, D K.

Affiliation

Lobo PJ; Medical Department, Farmitalia Carlo Erba (UK), Limited, St Albans, Hertfordshire.

BMJ ; 302(6772): 323-6, 1991 Feb 09.

Article in En | MEDLINE | ID: mdl-1900453

Subject(s)

Cost-Benefit Analysis; Leukemia, Myeloid, Acute/therapy; Models, Theoretical; Adolescent; Adult; Aged; Costs and Cost Analysis; Daunorubicin/therapeutic use; Humans; Idarubicin/therapeutic use; Leukemia, Myeloid, Acute/diagnosis; Leukemia, Myeloid, Acute/economics; Middle Aged; Prospective Studies; Remission Induction; Retrospective Studies

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Cost-Benefit Analysis / Models, Theoretical Type of study: Diagnostic_studies / Health_economic_evaluation / Observational_studies / Prognostic_studies Limits: Adolescent / Adult / Aged / Humans / Middle aged Language: En Journal: BMJ Journal subject: MEDICINA Year: 1991 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google